hayfever

Medical history and current medication reviewed. Client reports occasional migraine, managed with naproxen and rizatriptan as required. Currently taking the oral contraceptive pill. BMI 28 kg/m² and waist circumference 90 cm. Assessment consistent with overweight with central adiposity. Client's weight-loss goal is 9 kg.

Discussed treatment with Wegovy (semaglutide) and mechanism of action, including appetite regulation and increased satiety. Benefits, risks and potential adverse effects discussed, including nausea, vomiting, diarrhoea, constipation, abdominal pain and reduced appetite. Advised regarding dietary measures, smaller portion sizes and adequate fluid intake.

Contraception reviewed and advice provided regarding continued effective contraception. Advised that vomiting or severe diarrhoea may affect absorption of the oral contraceptive pill and to follow contraceptive guidance regarding additional precautions if required.

Following discussion, client wishes to proceed with treatment. Wegovy 0.25 mg subcutaneously once weekly commenced as prescribed. Advised to continue dietary and lifestyle measures. Weight, waist circumference, treatment response and tolerability to be monitored, with review prior to dose escalation. Weight-loss target is 9 kg.